Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1089 participants.
Also called NCT02128932
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,089 participants
- Sponsor
- Registry
-
NCT02128932 -
2013-004392-12
-
- Other papers using this trial's data
- Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
- Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials
- Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Croatia, France, Germany, India, Mexico, Netherlands, North Macedonia, Puerto Rico, Romania, Slovakia, Slovenia, South Africa, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02128932. Randomized; no masking; primary purpose treatment. Start 2014-08-04 (actual); primary completion 2015-09-03 (actual). Results posted on 2018-03-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes
- Acronym
- SUSTAIN™ 4
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- semaglutide
- Intervention (Drug)
- insulin glargine
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct02128932- Content hash
df3d4e829fae7d2bc1f09f2a3366e0904b36186eaab4e2c106ea12fa502a89bf